In United States the most common form of cancer in male population is prostate cancer that leads among the causes of cancer related deaths. There are various numbers of treatments that successfully can reverse prostate cancer in the early stages. There are also some cases when the reverse process happens for a short period and can have unwanted side effects.

To prevent the binding of testosterone to the receptor proteins scientist have created anti-androgen molecules that can enter cells. The drug molecules use the preferential binding to the androgen receptors. The purpose is that the preventing the androgens from binding to reduce the pregrowth activities.

Selective androgen receptor modulator (SARMs) has an expanding therapeutic use. The future of androgen therapy can be changed dramatically by using this novel class of androgen receptors (AR) ligands.  Continuous research for SARMs give scientist new perspectives in designing molecules that target AR in different tissues to act in the desired way for each key indication that benefits from androgen therapy. The process of developing molecules with distinct tissue specificity through the use of SARMs can provide the right answers to target only the affected tissues without side effects. We expect to see effective SARM therapy in prostate cancer

Formulations of testosterone esters or testosterone delivered to skin or injectable are the current used androgenic formulations for replacement therapy, The fluctuation in testosterone blood levels can be caused by marketed injectable forms of testosterone esters (such as propionate, cypionate or testosterone enanthate). The use of this injectable forms can produce supraphysiological concentration of testosterone in the early administration stage and subnormal levels towards the end of the period before the next injection.

This are causes of undesired side effects and unsatisfactory testosterone profile.  Skin irritation and the need of daily application of skin patches limit the acceptability and the usefulness of this form of therapy through the use of skin patches that in many cases can provide a better blood flow level of testosterone.

The development and discovery of SARMS is still at an early stage because many compounds are still under preclinical development and only some of them are completing phase I or phase II of clinical tests. Historically the first generations of nonsteroidal agents (quinoline analgos and aryl propionamide) are reported back in 1998. In 2003 the first SARMs that demonstrated the tissue selectivity in vivo were aryl propionamide. In 2006 followed tetrahydroquinoline (THQ) SARM followed in 2007 by hydantion. When tested on castrated animal models this anabolic SARMs demonstrated some degree of tissue selectivity having agonist activities in androgenic tissues (e.g., prostate) and anabolic tissues (e.g., levator ani muscle).

Higher degree tisue selectivity and improved specificity of AR in vivo pharmaconkinetic profiles undoubtedly will expand the clinical applications of androgens. Nevertheless the discovery and progress made by now with SARMs requires more study to determine if the molecular mechanism identified first in SERM can be applied to SARMs. Then we can talk about an effective SARM therapy of prostate cancer

Tissue - specific androgens development has a bright future especially because some of SARM agonist can affect positively the muscle strength in hypogonadal men and increase lean body mass but their main purpose is to treat cancer. Another benefit from SARM agonist development is that this can counteract frailty associated with aging.